Prognostic Significance of Pretreatment VEGF, Survivin, and Smac/DIABLO Serum Levels in Patients with Serous Ovarian Carcinoma

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2015 Jan 12

PMID 25577253

Citations 14

Authors

Bozena Dobrzycka

Beata Mackowiak-Matejczyk

Katarzyna Maria Terlikowska

Bozena Kulesza-Bronczyk

Maciej Kinalski

Slawomir Jerzy Terlikowski

Affiliations

Soon will be listed here.

Abstract

The second mitochondria-derived activator of caspase (Smac/DIABLO), vascular endothelial growth factor (VEGF), and survivin are known to play a significant role in the growth and development of numerous tumors. Serum concentrations of VEGF, survivin, and Smac/DIABLO were analyzed in 92 patients with serous ovarian cancer and 94 healthy controls. Values were correlated with clinicopathological characteristics and outcomes. The median pretreatment serum VEGF and survivin levels in patients with serous ovarian carcinoma were significantly higher, while Smac/DIABLO levels were significantly lower than that in healthy controls. Receiver operating characteristic (ROC) curve analysis showed that the best cutoff point for VEGF was determined to be 345 pg/ml; with 83 % sensitivity and 65 % specificity. For survivin, the cutoff point was 110 pg/ml and for Smac/DIABLO was 75 pg/ml, with 82 and 62 % sensitivity and 43 and 87 % specificity, respectively. In the patients group, higher VEGF and survivin levels and lower Smac/DIABLO levels in sera were significantly associated with poorer overall survival (OS) and disease-free survival (DFS). Preoperative measurement of serum VEGF, survivin, and Smac/DIABLO may be of help in early detection of serous ovarian cancer and may provide important information about the patient's outcome and prognosis.

Citing Articles

Comparison of Survivin Determination by Surface-Enhanced Fluorescence and Raman Spectroscopy on Nanostructured Silver Substrates.

Geka G, Kanioura A, Kochylas I, Likodimos V, Gardelis S, Dimitriou A Biosensors (Basel). 2024; 14(10).

PMID: 39451692 PMC: 11506520. DOI: 10.3390/bios14100479.

Clearance of apoptotic cells by neutrophils in inflammation and cancer.

Ramos C, Oehler R Cell Death Discov. 2024; 10(1):26.

PMID: 38218739 PMC: 10787834. DOI: 10.1038/s41420-024-01809-7.

The Current Status of the Liver Liquid Biopsy in MASH Related HCC: Overview and Future Directions.

Ugonabo O, Udoh U, Rajan P, Reeves H, Arcand C, Nakafuku Y Biomolecules. 2023; 13(9).

PMID: 37759769 PMC: 10526956. DOI: 10.3390/biom13091369.

Beneficial Proapoptotic Effect of Heterobasidion Annosum Extract in Colorectal Cancer Xenograft Mouse Model.

Sadowska A, Sawicka D, Godlewska K, Guzinska-Ustymowicz K, Zapora E, Sokolowska E Molecules. 2023; 28(3).

PMID: 36771018 PMC: 9919637. DOI: 10.3390/molecules28031352.

Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer.

Liu S, Wu M, Wang F J Cancer. 2021; 12(13):3976-3996.

PMID: 34093804 PMC: 8176232. DOI: 10.7150/jca.47695.

References

Cooper B, Ritchie J, Broghammer C, Coffin J, Sorosky J, Buller R . Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res. 2002; 8(10):3193-7. View

Adams J, Cory S . Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci. 2001; 26(1):61-6. DOI: 10.1016/s0968-0004(00)01740-0. View

Hefler L, Zeillinger R, Grimm C, Sood A, Cheng W, Gadducci A . Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol. 2006; 103(2):512-7. DOI: 10.1016/j.ygyno.2006.03.058. View

Chang J, Wong F, Liao C, Chen I, Wang H, Cheng A . Enzyme immunoassay for serum autoantibody to survivin and its findings in head-and-neck cancer patients. Clin Chem. 2004; 50(7):1261-4. DOI: 10.1373/clinchem.2003.026666. View

Mizutani Y, Katsuoka Y, Bonavida B . Low circulating serum levels of second mitochondria-derived activator of caspase (Smac/DIABLO) in patients with bladder cancer. Int J Oncol. 2012; 40(4):1246-50. PMC: 3584575. DOI: 10.3892/ijo.2012.1324. View

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh J, Comber H . Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013; 49(6):1374-403. DOI: 10.1016/j.ejca.2012.12.027. View

Chen C, Cheng W, Lee C, Chen T, KUNG C, Hsieh F . Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival. Gynecol Oncol. 1999; 74(2):235-40. DOI: 10.1006/gyno.1999.5418. View

Gadducci A, Ferdeghini M, Fanucchi A, Annicchiarico C, Ciampi B, Prontera C . Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome. Anticancer Res. 1999; 19(2B):1401-5. View

Harlozinska A, Sedlaczek P, Kulpa J, Grybos M, Wojcik E, van Dalen A . Vascular endothelial growth factor (VEGF) concentration in sera and tumor effusions from patients with ovarian carcinoma. Anticancer Res. 2004; 24(2C):1149-57. View

10.

Dobrzycka B, Terlikowski S, Bernaczyk P, Garbowicz M, Niklinski J, Chyczewski L . Prognostic significance of smac/DIABLO in endometrioid endometrial cancer. Folia Histochem Cytobiol. 2011; 48(4):678-81. DOI: 10.2478/v10042-010-0091-2. View

11.

Song Z, Yao X, Wu M . Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem. 2003; 278(25):23130-40. DOI: 10.1074/jbc.M300957200. View

12.

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

13.

Bandiera E, Franceschini R, Specchia C, Bignotti E, Trevisiol C, Gion M . Prognostic significance of vascular endothelial growth factor serum determination in women with ovarian cancer. ISRN Obstet Gynecol. 2012; 2012:245756. PMC: 3390037. DOI: 10.5402/2012/245756. View

14.

Qian X, Xi X, Li L . Nuclear survivin is associated with malignant potential in epithelial ovarian carcinoma. Appl Immunohistochem Mol Morphol. 2010; 19(2):126-32. DOI: 10.1097/PAI.0b013e3181e30dcd. View

15.

Liguang Z, Peishu L, Hongluan M, Hong J, Rong W, Wachtel M . Survivin expression in ovarian cancer. Exp Oncol. 2007; 29(2):121-5. View

16.

Mahner S, Woelber L, Eulenburg C, Schwarz J, Carney W, Jaenicke F . TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients. BMC Cancer. 2010; 10:139. PMC: 2873384. DOI: 10.1186/1471-2407-10-139. View

17.

Kehinde E, Maghrebi M, Anim J . The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers. Can J Urol. 2008; 15(2):3967-74. View

18.

Tempfer C, Obermair A, Hefler L, Haeusler G, Gitsch G, Kainz C . Vascular endothelial growth factor serum concentrations in ovarian cancer. Obstet Gynecol. 1998; 92(3):360-3. DOI: 10.1016/s0029-7844(98)00190-2. View

19.

Mita A, Mita M, Nawrocki S, Giles F . Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008; 14(16):5000-5. DOI: 10.1158/1078-0432.CCR-08-0746. View

20.

Oehler M, Caffier H . Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer. Anticancer Res. 2001; 20(6D):5109-12. View